Bulletin
Investor Alert

press release

April 8, 2022, 8:01 a.m. EDT

BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022

NEW YORK, April 08, Apr 08, 2022 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") /zigman2/quotes/204570570/composite BYSI +8.33% , a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial results for the quarter and year ended December 31, 2021 before market open on Thursday, April 14, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:00 am Eastern Time.

Conference Call & Webcast Details:
Date: Thursday, April 14
Time: 8:00 am Eastern Time
Toll Free: 877-451-6152
International: 201-389-0879
Conference ID: 13728822
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1542381&tp_key=4941bdf92a

About BeyondSpringHeadquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring's first-in-class lead asset, plinabulin, is being developed as a "pipeline in a drug" in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). The plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data. In the DUBLIN-3 study, a global, randomized, active controlled Phase 3 study, the plinabulin and docetaxel combination has met the primary endpoint of extending overall survival compared to docetaxel alone, in 2 [nd] /3 [rd] line NSCLC (EGFR wild type). Additionally, plinabulin is being broadly studied in combination with various immuno-oncology regimens that could boost the efficacy of PD-1/PD-L1 antibodies in seven different cancers. In addition to plinabulin, BeyondSpring's pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
arr@lifesciadvisors.com

COMTEX_405412757/2471/2022-04-08T08:00:39

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/204570570/composite
US : U.S.: Nasdaq
$ 1.56
+0.12 +8.33%
Volume: 240,091
July 1, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$56.06 million
Rev. per Employee
$17,776
loading...

Partner Center

Link to MarketWatch's Slice.